Roth Capital Raises Price Target on Spark Therapeutics (ONCE) to $90 Following Top-Line Results
Tweet Send to a Friend
Roth Capital reiterated a Buy rating on Spark Therapeutics (NASDAQ: ONCE), and raised the price target to $90.00 (from $71.00) ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
